Log in with your email address username.


[Correspondence] Dengue vaccination: a more ethical approach is needed

Since 2016, we have discussed the risks behind the recommendation and use in mass vaccination programmes of Dengvaxia—a dengue vaccine produced by Sanofi Pasteur (Lyon, France)—without immunological pretesting.1,2 By using differential equation models and statistical methods, my colleagues and I reassessed publicly available data from vaccine trials, and found a substantial reduction in the number of hospital admissions when Dengvaxia was given only to seropositive individuals (ie, those with a history of a previous infection from dengue virus), and a substantial increase in the number of hospital admissions over 5 years when administered without a previous population screening.